NewAmsterdam Pharma Company N.V.
Symbol: NAMS
NASDAQ
21.86
USDMarktpreis heute
87.5675
P/E-Verhältnis
0.0000
PEG-Verhältnis
1.95B
MRK Kapital
- 0.00%
DIV Rendite
NewAmsterdam Pharma Company N.V. (NAMS) Finanzberichte
Bilanz
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | |||
---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 340.4 | 438.5 | 53.1 | ||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.net-receivables | 0 | 1.9 | 1.9 | 4.3 | ||||
balance-sheet.row.inventory | 0 | -1.9 | 0 | 0 | ||||
balance-sheet.row.other-current-assets | 0 | 6.3 | 7.6 | 1.5 | ||||
balance-sheet.row.total-current-assets | 0 | 346.8 | 448.1 | 58.9 | ||||
balance-sheet.row.property-plant-equipment-net | 0 | 0.1 | 0.1 | 0.2 | ||||
balance-sheet.row.goodwill | 0 | 0 | 0.2 | 0 | ||||
balance-sheet.row.intangible-assets | 0 | 0.2 | 82.9 | 0 | ||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0.2 | 83.2 | 0 | ||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0.7 | ||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0.1 | 0 | ||||
balance-sheet.row.total-non-current-assets | 0 | 0.3 | 83.5 | 0.9 | ||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.total-assets | 0 | 347.1 | 531.6 | 59.8 | ||||
balance-sheet.row.account-payables | 0 | 16.9 | 11.1 | 6.2 | ||||
balance-sheet.row.short-term-debt | 0 | 0.1 | 0.1 | 0.1 | ||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 2.8 | ||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0.1 | 0.1 | ||||
Deferred Revenue Non Current | 0 | 1 | 4.5 | 0 | ||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||
balance-sheet.row.other-current-liab | 0 | 24 | 11.3 | 0 | ||||
balance-sheet.row.total-non-current-liabilities | 0 | 8.8 | 11.6 | 0.1 | ||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.capital-lease-obligations | 0 | 0.1 | 0.1 | 0.2 | ||||
balance-sheet.row.total-liab | 0 | 58.7 | 47.1 | 10 | ||||
balance-sheet.row.preferred-stock | 0 | 317 | 0 | 0 | ||||
balance-sheet.row.common-stock | 0 | 10.2 | 599.2 | 83.9 | ||||
balance-sheet.row.retained-earnings | 0 | -317 | -119.4 | -34.7 | ||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 4.4 | 4.7 | 0.6 | ||||
balance-sheet.row.other-total-stockholders-equity | 0 | 273.8 | 0 | 0 | ||||
balance-sheet.row.total-stockholders-equity | 0 | 288.4 | 484.5 | 49.8 | ||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 347.1 | 531.6 | 59.8 | ||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.total-equity | 0 | 288.4 | 484.5 | 49.8 | ||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||
Total Investments | 0 | 0 | 0 | 0.7 | ||||
balance-sheet.row.total-debt | 0 | 0.1 | 0.1 | 0.2 | ||||
balance-sheet.row.net-debt | 0 | -340.4 | -438.4 | -52.9 |
Kapitalflussrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | |||
---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -176.9 | -78.1 | -28.6 | ||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 0.1 | 0 | ||||
cash-flows.row.deferred-income-tax | 0 | 5.2 | 0 | -1.4 | ||||
cash-flows.row.stock-based-compensation | 0 | 24.6 | 3.9 | 1 | ||||
cash-flows.row.change-in-working-capital | 0 | 5.9 | 11.5 | 3.8 | ||||
cash-flows.row.account-receivables | 0 | 3.7 | -3.9 | -4.6 | ||||
cash-flows.row.inventory | 0 | -3.7 | 5.9 | -0.1 | ||||
cash-flows.row.account-payables | 0 | 5.1 | -2 | 8.6 | ||||
cash-flows.row.other-working-capital | 0 | 0.8 | 11.5 | 0 | ||||
cash-flows.row.other-non-cash-items | 0 | 0 | 70.6 | 0 | ||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | 0 | 0 | ||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||
cash-flows.row.other-investing-activites | 0 | 0 | 0.7 | 0 | ||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 0 | 0.7 | 0 | ||||
cash-flows.row.debt-repayment | 0 | 0 | -0.1 | 0 | ||||
cash-flows.row.common-stock-issued | 0 | 8.1 | 377.8 | 69 | ||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||
cash-flows.row.other-financing-activites | 0 | 0.8 | -2.5 | 0 | ||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 8.9 | 375.2 | 69 | ||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 5.1 | 1.6 | 1.4 | ||||
cash-flows.row.net-change-in-cash | 0 | -127.3 | 385.4 | 45.2 | ||||
cash-flows.row.cash-at-end-of-period | 0 | 340.4 | 438.5 | 53.1 | ||||
cash-flows.row.cash-at-beginning-of-period | 0 | 467.7 | 53.1 | 7.9 | ||||
cash-flows.row.operating-cash-flow | 0 | -141.2 | 8 | -25.2 | ||||
cash-flows.row.capital-expenditure | 0 | 0 | 0 | 0 | ||||
cash-flows.row.free-cash-flow | 0 | -141.2 | 8 | -25.2 |
Zeile der Gewinn- und Verlustrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | |||
---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 14.1 | 97.5 | 0 | ||||
income-statement-row.row.cost-of-revenue | 0 | 0 | 0.1 | 0 | ||||
income-statement-row.row.gross-profit | 0 | 14 | 97.4 | 0 | ||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||
income-statement-row.row.research-development | 0 | - | - | - | ||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||
income-statement-row.row.other-expenses | 0 | 0 | 0.1 | 0 | ||||
income-statement-row.row.operating-expenses | 0 | 189.2 | 104.5 | 29.8 | ||||
income-statement-row.row.cost-and-expenses | 0 | 189.2 | 104.5 | 29.8 | ||||
income-statement-row.row.interest-income | 0 | 11.3 | 0 | 0 | ||||
income-statement-row.row.interest-expense | 0 | 0 | 0.3 | 0.2 | ||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||
income-statement-row.row.total-other-income-expensenet | 0 | -5.2 | -10.5 | 1.2 | ||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0.1 | 0 | ||||
income-statement-row.row.total-operating-expenses | 0 | -5.2 | -10.5 | 1.2 | ||||
income-statement-row.row.interest-expense | 0 | 0 | 0.3 | 0.2 | ||||
income-statement-row.row.depreciation-and-amortization | 0 | 0 | 60.7 | 0 | ||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||
income-statement-row.row.operating-income | 0 | -183 | -67.6 | -29.8 | ||||
income-statement-row.row.income-before-tax | 0 | -176.9 | -78.1 | -28.6 | ||||
income-statement-row.row.income-tax-expense | 0 | 0 | 70.8 | 0.2 | ||||
income-statement-row.row.net-income | 0 | -176.9 | -148.9 | -28.8 |
Häufig gestellte Frage
Wie hoch ist die NewAmsterdam Pharma Company N.V. (NAMS) Gesamtvermögen?
NewAmsterdam Pharma Company N.V. (NAMS) Gesamtvermögen ist 347097000.000.
Wie hoch ist der Jahresumsatz des Unternehmens?
Der Jahresumsatz ist N/A.
Wie hoch ist die Gewinnspanne des Unternehmens?
Die Gewinnmarge des Unternehmens ist 1.000.
Wie hoch ist der freie Cashflow des Unternehmens?
Der freie Cashflow ist -0.345.
Wie hoch ist die Nettogewinnspanne des Unternehmens?
Die Nettogewinnmarge ist 0.206.
Wie hoch sind die Gesamteinnahmen des Unternehmens?
Der Gesamtertrag ist -0.335.
Was ist der NewAmsterdam Pharma Company N.V. (NAMS) nettogewinn (reingewinn)?
Der Nettogewinn (Nettoeinkommen) ist -176937000.000.
Wie hoch ist die Gesamtverschuldung des Unternehmens?
Die Gesamtverschuldung ist 60000.000.
Wie hoch ist der Betriebsaufwand?
Die Betriebsausgaben sind 189195000.000.
Wie hoch ist der Bargeldbestand des Unternehmens?
Die Unternehmensliquidität ist 0.000.